Anavex has made headlines with its promising developments in Alzheimer’s treatment. The biopharmaceutical company, known for focusing on neurodegenerative and neurodevelopmental disorders, has recently shared groundbreaking results from its Phase 2b/3 trial of the drug blarcamesine (ANAVEX®2-73). The trial, which enrolled over 500 participants, was carefully designed to assess the […]